{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:32:44Z","timestamp":1793320364700,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical evidence comparing the renal impact of proton pump inhibitors (PPIs) and Histamine-2 receptor antagonists (H2RAs) in patients with chronic kidney disease (CKD) receiving traditional non-steroidal anti-inflammatory drugs (tNSAIDs) is lacking. We evaluated CKD progression risk associated with PPIs versus H2RAs within a tNSAID-treated cohort to inform clinical prescribing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used South Korean nationwide claims data (2018\u20132023). Stabilized inverse probability of treatment weighting (SIPTW) balanced the cohorts. Restricted cubic spline Cox regression addressed non-linear associations between CKD progression and cumulative exposure to tNSAIDs and acid suppressants (PPIs or H2RAs). Sensitivity analyses addressing unspecified CKD stages confirmed the robustness of the primary findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 141 093 tNSAID initiators with CKD prescribed PPIs (n = 5315) or H2RAs (n = 7112), PPIs were associated with higher CKD progression risk than H2RAs (adjusted hazard ratio [aHR] 1.38, 95% CI 1.10\u20131.74). Baseline comorbidities\u2014hypertension (aHR 2.03, 95% CI 1.37\u20132.99]), diabetes (1.69 [1.29\u20132.21]), and a history of kidney disease (1.43 [1.13\u20131.81])\u2014and prior diuretic use (2.00 [1.56\u20132.58]) were associated with increased risk of CKD progression. In contrast, dapagliflozin or empagliflozin use was protective (0.49 [0.27\u20130.89]). The risk of CKD progression for PPIs relative to H2RAs was most pronounced in females, those with CKD stage 3, patients aged \u226571 years, and those with 1\u201315 days of treatment (all P &amp;lt; .05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that H2RAs may be associated with a lower risk of CKD progression than PPIs in tNSAID users with CKD, potentially offering a safer alternative when PPI therapy is not indispensable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag176","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:39:44Z","timestamp":1781955584000},"page":"1687-1696","source":"Crossref","is-referenced-by-count":0,"title":["Chronic kidney disease progression with proton pump inhibitors versus H2 receptor antagonists in NSAID users"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7016-5124","authenticated-orcid":false,"given":"Susin","family":"Park","sequence":"first","affiliation":[{"name":"College of Pharmacy, Kyungsung University , Busan ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-9880","authenticated-orcid":false,"given":"Pusoon","family":"Chun","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University , Gimhae, Gyeongnam \u00a0","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026102919572686300_aajag176-B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3121\/cmr.2007.698","article-title":"An evidence based update on nonsteroidal anti-inflammatory drugs","volume":"5","author":"Ong","year":"2007","journal-title":"Clin Med Res"},{"key":"2026102919572686300_aajag176-B2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1053\/j.ajkd.2020.03.023","article-title":"NSAIDs in CKD: are they safe?","volume":"76","author":"Baker","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026102919572686300_aajag176-B3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ckj\/sfz054","article-title":"Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care","volume":"13","author":"Lefebvre","year":"2019","journal-title":"Clin Kidney J"},{"key":"2026102919572686300_aajag176-B4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s10157-024-02570-y","article-title":"Estimating the prevalence of chronic kidney disease in the older population using health screening data in Japan","volume":"29","author":"Kobayashi","year":"2025","journal-title":"Clin Exp Nephrol"},{"key":"2026102919572686300_aajag176-B5","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1186\/s12889-025-24005-3","article-title":"A study of demographic and clinical characteristics of consumers of non-steroidal anti-inflammatory drugs: a large population-based study utilizing enrollment phase data from the tabari cohort","volume":"25","author":"Hessami","year":"2025","journal-title":"BMC Public Health"},{"key":"2026102919572686300_aajag176-B6","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.3748\/wjg.v29.i44.5882","article-title":"Changing trends and characteristics of peptic ulcer disease: a multicenter study from 2010 to 2019 in Korea","volume":"29","author":"Choi","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2026102919572686300_aajag176-B7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/ajg.2009.115","article-title":"Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2026102919572686300_aajag176-B8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.5009\/gnl20246","article-title":"Clinical guidelines for drug-related peptic ulcer, 2020 revised edition","volume":"14","author":"Joo","year":"2020","journal-title":"Gut Liver"},{"key":"2026102919572686300_aajag176-B9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcph.2147","article-title":"Effectiveness and safety of histamine H2 receptor antagonists: an umbrella review of meta-analyses","volume":"63","author":"Meng","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"2026102919572686300_aajag176-B10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2026102919572686300_aajag176-B11","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1681\/ASN.2015121377","article-title":"Proton pump inhibitors and risk of incident CKD and progression to ESRD","volume":"27","author":"Xie","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2026102919572686300_aajag176-B12","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","article-title":"Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury","volume":"91","author":"Xie","year":"2017","journal-title":"Kidney Int"},{"key":"2026102919572686300_aajag176-B13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s12882-024-03867-6","article-title":"Accelerated risk of renal disease progression in pre-ESRD patients with proton pump inhibitors use: a nationwide population-based study","volume":"25","author":"Huang","year":"2024","journal-title":"BMC Nephrol"},{"key":"2026102919572686300_aajag176-B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-078032","article-title":"Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study","volume":"14","author":"Kim","year":"2024","journal-title":"BMJ Open"},{"key":"2026102919572686300_aajag176-B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203878","article-title":"Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"key":"2026102919572686300_aajag176-B16","author":"HIRA Bigdata Open Portal"},{"key":"2026102919572686300_aajag176-B17","author":"Korean Classification of Diseases Information Center (KOICD)"},{"key":"2026102919572686300_aajag176-B18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/pds.5398","article-title":"Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data","volume":"31","author":"Paik","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026102919572686300_aajag176-B19","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.3390\/jcm11195612","article-title":"Impact of acid suppression therapy on renal and survival outcomes in patients with chronic kidney disease: a Taiwanese nationwide cohort study","volume":"11","author":"Chen","year":"2022","journal-title":"J Clin Med"},{"key":"2026102919572686300_aajag176-B20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","article-title":"Association between proton pump inhibitor use and risk of progression of chronic kidney disease","volume":"153","author":"Klatte","year":"2017","journal-title":"Gastroenterology"},{"key":"2026102919572686300_aajag176-B21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000525561","article-title":"Facing the challenge of drug-induced acute interstitial nephritis","volume":"147","author":"Sanchez-Alamo","year":"2023","journal-title":"Review Nephron"},{"key":"2026102919572686300_aajag176-B22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/MCG.0000000000001035","article-title":"The association between proton pump inhibitor use with acute kidney injury and chronic kidney disease","volume":"52","author":"Kamal","year":"2018","journal-title":"Review J Clin Gastroenterol"},{"key":"2026102919572686300_aajag176-B23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1053\/j.ajkd.2004.12.005","article-title":"Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population","volume":"45","author":"Huerta","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"2026102919572686300_aajag176-B24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/0895-4356(94)90170-8","article-title":"Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research","volume":"47","author":"Moride","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"2026102919572686300_aajag176-B25","doi-asserted-by":"publisher","first-page":"280.e1","DOI":"10.1016\/j.amjmed.2006.02.015","article-title":"NSAID use and progression of chronic kidney disease","volume":"120","author":"Gooch","year":"2007","journal-title":"Am J Med"},{"key":"2026102919572686300_aajag176-B26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/biomedicines10020407","article-title":"Glomerular biomechanical stress and lipid mediators during cellular changes leading to chronic kidney disease","volume":"10","author":"Sharma","year":"2022","journal-title":"Biomedicines"},{"key":"2026102919572686300_aajag176-B27","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/ndt\/gfae027","article-title":"Glomerular hyperfiltration as a therapeutic target for CKD","volume":"39","author":"Kanbay","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026102919572686300_aajag176-B28","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/ndt\/gfad271","article-title":"Risk factor analysis for a rapid progression of chronic kidney disease","volume":"39","author":"Vestergaard","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026102919572686300_aajag176-B29","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical pPractice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026102919572686300_aajag176-B30","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards actualizing the value potential of Korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data","volume":"32","author":"Kim","year":"2017","journal-title":"J Korean Med Sci"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/8\/1687\/70935235\/aajag176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/8\/1687\/70935235\/aajag176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:57:35Z","timestamp":1793318255000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/8\/1687\/8780921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,9,3]]},"published-print":{"date-parts":[[2026,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag176","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,3]]}}}